NCT06777485
Recruiting
Not Applicable
China Liver Cancer Clinical Registry Cohort Database (HEAL)
Anhui Provincial Hospital38 sites in 1 country10,000 target enrollmentJanuary 1, 2025
DrugsAnti-Tumor Drugs
Overview
- Phase
- Not Applicable
- Intervention
- Procedure/Surgery treatment
- Conditions
- Not specified
- Sponsor
- Anhui Provincial Hospital
- Enrollment
- 10000
- Locations
- 38
- Primary Endpoint
- OS
- Status
- Recruiting
- Last Updated
- 8 months ago
Overview
Brief Summary
This study was led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close cooperation with many participating units across the country, to establish a standardized clinical information database of hepatocellular carcinoma cohorts, which will provide a guarantee for conducting high-quality real-world clinical studies and clinical research.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age ≥ 18 years, no gender limit
- •Patients without surgery are initially diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of imaging and laboratory tests, or patients with surgery are diagnosed with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, or metastatic hepatocellular carcinoma based on the results of pathologic tests
- •Signed informed consent, good compliance, willingness to accept follow-up and provide blood and postoperative pathology residual samples
Exclusion Criteria
- •Combination of severe central nervous system disease, respiratory disease, autoimmune disease, chronic renal insufficiency, long-term use of immunosuppressive drugs, combination of severe uncontrolled infections
- •Concurrent active cardiovascular disease, cerebrovascular accident within 6 months, myocardial infarction, unstable angina pectoris, or congestive heart failure of class II or greater according to the New York Heart Association criteria, severe arrhythmia requiring medication
- •Pregnant or breastfeeding women
- •Participation in other therapeutic clinical trials during the course of the patient's illness in which the treatment cannot be specified or information about the treatment cannot be collected
Arms & Interventions
Liver Cancer
Observation of clinical routine treatment in patients with Liver cancer
Intervention: Procedure/Surgery treatment
Liver Cancer
Observation of clinical routine treatment in patients with Liver cancer
Intervention: Anti-Tumor Drugs
Outcomes
Primary Outcomes
OS
Time Frame: 10 years
Time from enrollment to first recorded occurrence of death from any cause
Secondary Outcomes
- RFS(10 years)
- Survival time after recurrence(10 years)
Study Sites (38)
Loading locations...
Similar Trials
Recruiting
Not Applicable
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCCCarcinoma; HepatocellularNCT05596630Second Affiliated Hospital, School of Medicine, Zhejiang University40
Recruiting
Not Applicable
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver CancerLiver CancerLiver CirrhosisFatty LiverHepatitisNCT05719480Nanfang Hospital, Southern Medical University2,000
Recruiting
Not Applicable
Study to compile a register of the Liver Cancer Center Heidelberg (LCCH-Register).C23C22C24Malignant neoplasm of gallbladderMalignant neoplasm of liver and intrahepatic bile ductsMalignant neoplasm of other and unspecified parts of biliary tractDRKS00019901niversitätsklinikum Heidelberg6,000
Recruiting
Not Applicable
Correlation Study of Lipid Metabolites as Markers of Hepatocellular CarcinomaHepatocellular CarcinomaNCT06623474Nanfang Hospital, Southern Medical University900
Completed
Not Applicable
Hepatocellular Carcinoma Registry for Turkey (3K Trial)Hepatocellular CarcinomaNCT01473121Bayer600